行情

LIFE

LIFE

aTyr Pharma
NASDAQ

实时行情|Nasdaq Last Sale

2.549
-0.001
-0.04%
交易中 15:24 04/02 EDT
开盘
2.470
昨收
2.550
最高
2.700
最低
2.452
成交量
4.39万
成交额
--
52周最高
10.08
52周最低
2.130
市值
2,383.86万
市盈率(TTM)
-0.3471
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LIFE价格均价为11.50,最高价位15.00,最低价为8.00。

EPS

LIFE 新闻

更多
  • aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 6天前
  • aTyr Pharma EPS misses by $0.06, misses on revenue
  • seekingalpha · 6天前
  • Atyr Pharma (LIFE) Reports Q4 Loss, Lags Revenue Estimates
  • Zacks · 6天前
  • aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
  • GlobeNewswire · 6天前

所属板块

生物技术和医学研究
+1.93%
制药与医学研究
+1.93%

热门股票

代码
价格
涨跌幅

LIFE 简况

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
展开

微牛提供aTyr Pharma Inc(NASDAQ-LIFE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LIFE股票新闻,以帮助您做出投资决策。